About Syrrx
Syrrx is a Healthcare company based in San Diego (United States) founded in 1999, and was acquired by Takeda in February 2005. Provider of drug targets research and clinical trial services. Syrrx has raised $79 million across 4 funding rounds from investors including Canadian Imperial Bank of Commerce, Takeda Pharmaceuticals and SBIR. Its focus areas include Biopharma Outsourcing, CRO, Drug Discovery and Structural Biology. Its competitors include Shamrock Structures, PTM Thera and Deep Forest Sciences; 1 of its 3 listed competitors has raised funding.
Company details
Founded in 1999 and based in San Diego, United States, Syrrx operates in the biotechnology sector. Efforts are directed toward identifying three-dimensional structures of validated drug targets via high-throughput structural biology. Structure-based drug design is applied to develop candidates for metabolic diseases, cancer, and inflammation. A partnership is maintained for commercializing DPP IV inhibitors aimed at type 2 diabetes and related conditions.
- Total Equity Funding$79M (USD)
in 4 rounds
- Latest Funding Round$100K (USD), Grant
Oct 2001
- InvestorsCanadian Imperial Bank of Commerce
& 8 more
- Acquired byTakeda
(Feb 2005)
Funding Insights of Syrrx
Syrrx has successfully raised a total of $79M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $100 thousand completed in October 2001. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $79M
- Total Rounds 4
- Last Round Grant — $100,000
- First Round $5M
(Aug 2000)
- Investors Count 8
All 4 funding rounds of Syrrx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2001 | $100,000 | Grant | – | – | |
| Jan 2001 | $54M | Series C | – | Lombard Odier | |
| Oct 2000 | $20M | Series B | – | MPM Capital | – |
| Aug 2000 | $5M | Series A | – | Bay City Capital, Versant Ventures | – |
9 investors in total: 9 institutional.
Investors in Syrrx
Syrrx has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Canadian Imperial Bank of Commerce, Takeda Pharmaceuticals and SBIR.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Stage-agnostic investments in US life-sciences sectors are managed. | baycitycapital.com | San Francisco, United States | ||
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999. | versantventures.com | |||
| cmea.com | ||||
Federal innovation and scientific achievement services are provided. | 1982 | sbir.gov | Lithia Springs, United States | |
Provider of wealth management services | 1796 | lombardodier.com | Geneva, Switzerland | |
Diversified asset management services are offered globally by Invesco. | invesco.com | Atlanta, United States | ||
Commercial banking services are provided to individuals and businesses. | 1867 | cibc.com | Toronto, Canada | |
Invests in biotech firms developing life-saving drugs and technologies. | mpmcapital.com | |||
Takeda Pharmaceuticals is engaged in developing innovative medicines globally. | 1781 | takeda.com | Tokyo, Japan |
Investor details for Syrrx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Syrrx
4 dated milestones of Syrrx across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Syrrx is founded.
- Funding First funding round of $5.0M.
- Funding Latest funding round, Grant, of $100K.
- Exit Acquired by Takeda.
Competitors of Syrrx
Syrrx has 3 listed competitors in our database, 1 of them funded. They include Shamrock Structures, PTM Thera and Deep Forest Sciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| shamrockstructures.com | 2003 | Woodridge, United States | 13 | Proteomic services like protein cloning, expression, purification and crystallization | ||
| ptmthera.com | 2019 | San Francisco, United States | Drug development services are provided by PTM Thera. | |||
| deepforestsci.com | 2021 | Fremont, United States | $150,000 | Structural biology-based drug discovery services are provided. |
Detailed competitors of Syrrx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Syrrx
The website of Syrrx (syrrx.com) receives about 2.9K visits a month.
- Monthly visits2.9K
▲ 20.7% vs previous month
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Syrrx (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Syrrx
Syrrx was founded in 1999 and raised its 1st funding round 1 year after it was founded.
Syrrx is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Syrrx is a funded company, having raised a total of $79M across 4 funding rounds to date. The company's 1st funding round was a Series A of $5M, raised on Aug 2000.
Founded in 1999 and based in San Diego, United States, Syrrx operates in the biotechnology sector. Efforts are directed toward identifying three-dimensional structures of validated drug targets via high-throughput structural biology. Structure-based drug design is applied to develop candidates for metabolic diseases, cancer, and inflammation. A partnership is maintained for commercializing DPP IV inhibitors aimed at type 2 diabetes and related conditions.
Syrrx's top competitors include Shamrock Structures, PTM Thera and Deep Forest Sciences.
Syrrx has 9 investors. Key investors include Canadian Imperial Bank of Commerce, Takeda Pharmaceuticals, SBIR, Lombard Odier, and Bay City Capital.
Yes. Syrrx was acquired by Takeda in February 2005.